Eli Lilly's experimental gene-editing therapy VERVE-102 shows promise as one-time treatment for high cholesterol
By
Yi-Jin Yu
2d ago· 2 min readenNews
70/100
Toasty
Bagelometer↗
Not artisan, but a perfectly fine bagel. Hits the spot.
Score70TypenewsSentimentpositive
Summary
Eli Lilly is testing VERVE-102, an experimental gene-editing therapy for high cholesterol that could be administered as a one-time infusion over four hours, replacing daily pills or regular shots. The therapy targets the PCSK9 gene in the liver to regulate cholesterol levels. An early study of 35 patients showed promising results, though the content is cut off and details on efficacy and safety are incomplete.
Key quotes
· 3 pulledDrugmaker Eli Lilly is testing a new experimental drug that could be a game changer in treating high cholesterol, it said.
VERVE-102 is a gene-editing therapy that switches off the PCSK9 gene in the liver that makes a protein that regulates cholesterol levels, according to a news release from Eli Lilly this week.
Researchers say the new drug, called VERVE-102, could be administered to patients with a one-time infusion over the course of approximately four hours instead of having patients take a daily pill or regular shots.
Drugmaker Eli Lilly is testing a new experimental drug that could be a game changer for treating high cholesterol.
